Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthesis.
Hypoxia is a potent stimulus for lung vascular and interstitial remodeling during development, and in diseases such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and asthma (1-3). Long-term (chronic) hypoxia modulates gene expression and thus can induce structural changes in the lung (4) . These changes include increased fibroblast and vascular smooth muscle cell proliferation and enhanced deposition of extracellular matrix, resulting in sustained increases in pulmonary vascular resistance (4, 5) . In the response to hypoxia, the release of short-lived mediators such as nitric oxide (NO) represents a key mechanism in the control of vascular resistance and vascular cell proliferation (6, 7) . The role of NO production in the hypoxic lung, however, remains controversial. Several studies have shown decreased NO production during alveolar hypoxia, which may be due to O 2 substrate limitation, NO synthase (NOS) expression, or NOS activity, while other studies have shown the opposite (6) . In recent years, our basic understanding of the control of NOS has advanced with the discovery of endogenous inhibitors of NOS, such as asymmetric dimethylarginine (ADMA) and N G -monomethyl-L-arginine (L-NMMA). ADMA and L-NMMA both belong to the class of naturally occurring analogues of the nitric oxide (NO) precursor L-arginine, and act as endogenous inhibitors of all NOS isoforms (8, 9) .
ADMA and L-NMMA are generated through degradation of cellular proteins that contain methylated arginine residues (10) . It has been demonstrated that, during post-translational modification of many intracellular proteins, nitrogen atoms of arginine residues can be covalently mono-or di-methylated by the action of protein arginine methyltransferases (PRMT), a recently discovered gene family (11). Up to now, eight PRMT isoforms have been cloned and characterized in mammals, displaying varying degrees of substrate specificity (10) (11) (12) . PRMTs catalyze the transfer of one or two methyl groups provided by S-adenosyl-methionine to select 4 target proteins, either in symmetric configuration (leading to symmetric dimethylarginine, SDMA), or in asymmetric configuration (leading to ADMA). PRMTs can be divided into two groups: type I PRMT catalyze ADMA formation in select target proteins, whereas type II PRMT catalyze SDMA formation through methylation of both guanidino nitrogens. In addition, all PRMT can also catalyze monomethylation, leading to the formation of L-NMMA. Free cellular ADMA and L-NMMA can be hydrolyzed by dimethylarginine dimethylaminohydrolases (DDAH) (10) .
The biological impact of protein arginine methylation remains to be fully elucidated, but it has been shown to modify protein functions by regulating protein-protein interactions, both negatively and positively. Furthermore, arginine methylation in target proteins plays a role in the regulation of RNA binding, control of transcription, DNA repair, protein localization, signal transduction, and recycling of membrane receptors (11). Large scale proteomic approaches have unraveled a potentially broad range of substrate proteins for PRMT methylation, suggesting a significant role for arginine methylation in cellular processes (13) . Moreover, increased methylation of cellular proteins by PRMT may significantly contribute to the level of free methylarginines via protein degradation, as direct methylation of free arginines has not been demonstrated.
Circulating ADMA levels have been assessed in a variety of systemic cardiovascular diseases, and are increased in conditions associated with hypoxia, renal failure, pulmonary hypertension, heart failure, or hypercholesterolemia (10, 14) . A recent study by Smith et al. demonstrated that pathophysiological concentrations of ADMA are sufficient to elicit distinct changes in gene expression of coronary endothelial cells, suggesting that increased extracellular ADMA levels also regulate cellular functions (15) . Despite the wealth of information available 5 on circulating plasma ADMA levels, however, no studies have thus far correlated tissue ADMA and PRMT levels. The tissue expression and localization of PRMT isoforms in the lung remains entirely unknown. In this study, we therefore sought to characterize the expression and localization pattern of PRMT isoforms in the lung, and investigated whether PRMT expression and lung ADMA levels changed during exposure to chronic hypoxia.
MATERIALS AND METHODS

Mouse Models
All animal studies were performed according to the guidelines of the University of Giessen and approved by the local authorities (Regierungspräsidium Giessen, no. II25.3-19c20-15; GI20/10-Nr. 22/2000) . Male BALB/c mice (20 to 22 g; Charles River, Sulzfeld, Germany) were exposed to normobaric normoxia (FiO 2 of 0.21) or hypoxia (FiO 2 of 0.10) in a ventilated chamber system (16) . After the indicated times under hypoxic conditions, the lungs were flushed via a catheter in the pulmonary artery with Krebs Henseleit buffer (125 mM NaCl, 4.3 mM KCl, 1.1 mM KH 2 PO 4 , 2.4 mM CaCl 2 , 1.3 mM MgCl 2 , 23.8 mM NaHCO 3 , and 13.32 mM glucose, equilibrated with 5.3% CO 2 ) and pressure-fixed (20 cm H 2 O) with 4% (w/v) buffered paraformaldehyde in phosphate buffered saline (PBS, pH 7.4). Tracheas were ligated and lungs/hearts were excised en bloc, submerged in 4% (w/v) paraformaldehyde in PBS overnight, and processed for paraffin embedding and sectioning. Lungs were cut into 3 µm sections and processed as described for immunohistochemistry (17) . A separate set of lungs was immediately removed and snap frozen in liquid nitrogen for RNA and protein extraction. Hematocrit and right heart hypertrophy were measured in all study animals. To measure the ratio of right ventricle 6 wall/left ventricle plus septum (RV/LV+S), the right ventricular walls were trimmed from the left ventricles plus septa, air-dried, and weighed. Similarly, timed pregnant mice were sacrificed at the indicated dates, and pups removed surgically. Lungs were excised from pups under magnification and immediately processed for further analysis, as described above. 
RT-PCR
Western blot analysis
Frozen lung tissues were homogenized in lysis buffer [20 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton-X 100, 2.5 mM sodium pyrophosphate, and (1:2500, clone B-7, Santa Cruz, CA). Densitometric analysis (n ≥ 6 for each group) was performed with Quantity One (Bio-Rad) and analyzed using two-tailed Student's t-test.
Immunohistochemical analysis
Whole lung sections were deparaffinized in xylene for 3 x 5 min and rehydrated in 100% ethanol for 2 x 1 min, 95% ethanol for 2 x 1 min, and PBS for 1 x 2 min (17). Antigen retrieval was performed in a pressure cooker using citrate buffer unmasking solution at pH 6.0 
Isolation of basic amino acids from lung crude extracts
Snap-frozen mouse lungs were homogenized in liquid nitrogen, followed by addition of ice-cold lysis buffer [20 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 % (v/v) Triton X-100, 2 mM Na 3 VO 4 ]. Homogenized tissues were incubated for 1 h on ice and centrifuged for 15 min at 10,000 × g. Crude extracts were subjected to fractionation on Oasis MCX cation-exchange SPE columns (Waters, Eschborn, Germany). Crude extracts (100 µl of each sample) were adjusted to a final volume of 1 ml with PBS. All conditioning, washing, and elution steps were performed on a vacuum-manifold with a capacity of 24 columns (Waters) at a flow rate of 0.5 ml/min. The SPE columns were conditioned with 2 ml of methanol/water/ammonia (50:45:5, v/v/v) followed by 2 ml PBS prior to sample application.
Samples were passed through SPE cartridges and contaminating components rinsed off with 2 ml of 0.1 M HCl followed by 2 ml methanol. Basic compounds were eluted with 1 ml of methanol/water/ammonia (50:45:5, v/v/v) and dried under nitrogen stream at 65°C (18) .
Derivatization and chromatographic separation
Amino acid eluates were redissolved in 230 µl of distilled water and centrifuged at 10,000
× g for 2 min to remove particulate matter prior to derivatization for HPLC. Fluorescent amino acid derivatives were separated on a SunFire TM C18 column (4.6 × 150 mm; 3.5 µm particle size; 100 Å pore size) with a µBondapak TM C18 guard column (10 µM) at 30°C
and a flow rate of 1.1 ml/min (all columns were from Waters). After injection of the sample (125 µl), separation was performed under isocratic conditions with 8.8% (v/v) acetonitrile in 25 mM potassium phosphate buffer (pH 6.8) as a solvent. Isocratic conditions were maintained for 30 min. In order to elute strongly bound compounds, the column was flushed with acetonitrile/water (50:50, v/v) for 2 min and re-equilibrated under isocratic conditions for 10 min prior to the next injection. Fluorescent derivatives were detected at excitation and emission wavelengths of 330 and 450 nm, respectively. L-arginine and ADMA were quantified by two separation steps. For the detection of ADMA, the gain of the detector was switched to a hundred-fold higher sensitivity. Calibration was performed on the base of the peak area using six combined standards spanning the range 1.5 to 450 pmol (60 nM to 18 µM) for L-Arg, 0.15 to 45 pmol (6 nM to 1.8 µM) for ADMA, and 0.09 pmol to 9 pmol (3.6 nM to 0.36 µM) for SDMA (all from Sigma, St.
Louis, MO) (18) .
RESULTS
PRMT Expression in Mouse Lung
We initially characterized full-length PRMT1-7 transcripts by cloning and sequencing full-length cDNAs from adult mouse lung. Mouse PRMT1-6 isoforms have previously been cloned from the mouse, however, our report constitutes the first description of PRMT7 from the mouse. This PRMT7 sequence has been deposited in the GenBank TM database (accession number AY673972). Figure 1A demonstrates strong expression of all PRMT isoforms in mouse lung, with no evidence of splice isoforms expressed. All sequences were fully sequenced and shown to be identical to the provisional RefSeq depositions at GenBank. We next analyzed whether lung PRMT levels were regulated during lung development. To do so, mouse lungs were harvested at distinct intervals from E13 to adults and subjected to RT-PCR analysis. As depicted in Figure 1B , PRMT1-7 were abundantly expressed throughout development. While no changes in expression levels were observed in cases of PRMT1, 5, and 7, distinct changes were noted for PRMT2, 3, 4, and 6. While PRMT3 and 4 expression peaked at P7 with a decline thereafter, PRMT2 and 6 expression steadily increased to adulthood ( Figure 1B ). These data must be cautiously interpreted, however, since mRNA and protein expression levels do not always correlate, as was evident in our hypoxia studies (below).
We then characterized whether PRMT1-6 RNA expression was altered when mice were Similarly, the hematocrit values increased from 43 ± 0 under normoxia, 53.6 ± 0.6 after 7 days of hypoxia, to 56.6 ± 1.2 after 21 days of hypoxia (p<0.01). and the loading control HSC70 did not differ between samples from normoxic and hypoxic mice, PRMT2 RNA levels were upregulated after 3 weeks of hypoxia ( Figure 2A ). As represented in Figure 2B , Western blot analyses revealed an even higher upregulation of PRMT2 protein levels under hypoxia. This effect was specific for PRMT2, as the expression of all other PRMTs investigated did not change significantly in the lungs of hypoxic mice ( Figure 2B, 3) . To quantify PRMT expression levels, we performed densitometric analyses from at least 3 different Western blots each. Densitometry indicated a significant difference in PRMT2 protein expression under hypoxia, whereas we did not observe significant expression differences for all other PRMT isoforms ( Figure 3 ).
PRMT Localization in Mouse Lung
To investigate the cellular localization of PRMT enzymes in the lung in detail, we performed immunohistochemical analyses on lung sections obtained from normoxic and hypoxic animals. PRMT2 was expressed in the cytosol of some, but not all airway epithelial cells in the lungs of mice exposed to normoxic conditions ( Figure 4) . In contrast to other PRMT isoforms, PRMT2 expression levels changed after hypoxic exposure, where staining became evident in alveolar type II cells and macrophages ( Figure 5 ). The product of PRMT activity, methylated proteins, were also localized to alveolar type II cells and macrophages using an antibody raised against mono-and dimethylated proteins ( Figure 5 ).
Methylated Proteins in Mouse Lung
To analyze whether the end-product of PRMT activity, free cellular ADMA, was also found in the mouse lung, we developed an HPLC-based method to accurately quantify ADMA in crude tissue extracts. Using this protocol, ADMA and arginine were fully separated from other components of lung lysates ( Figure 6A and B) . To confirm the identity of ADMA, crude tissue extract was spiked with ADMA ( Figure 6B , lower panel). Taken together, this method permits the simultaneous quantification of arginine and ADMA in crude tissue extracts. As depicted in Figure 6C , hypoxic conditions caused a significant increase in free cellular ADMA levels after 7 days (19.4 ± 2.4 pmol/mg protein vs. 9.2 ± 0.7 pmol/mg protein) and a moderate increase after 21 days (12.3 ± 1.9 pmol/mg protein), indicating increased PRMT activity. Interestingly, we also observed a slight reduction in free arginine (813 ± 107 pmol/mg protein vs. 1219 ± 180 pmol/mg protein) after 21 days, while arginine levels after 7 days did not change significantly ( Figure 6C ).
14
In conclusion, lung ADMA levels and ADMA/arginine ratios were increased under hypoxic conditions (Table 2) .
DISCUSSION
The key observations of this study are that (a) PRMT isoforms are expressed at the mRNA and protein levels in the mouse lung, and are localized predominantly in airway and alveolar type II epithelial cells; (b) PRMT2 expression is selectively upregulated in alveolar epithelial cells in response to chronic hypoxia; and (c) increased PRMT2 expression coincides with increased tissue ADMA levels and decreased L-Arg/ADMA ratios in hypoxic mouse lungs.
These data thus support an important role for PRMT enzymes in the lung, and suggest an as yet unappreciated role for PRMT-mediated ADMA generation in pulmonary homeostasis and hypoxia-induced changes in lung epithelial cells.
PRMTs are the only group of enzymes known to methylate arginine residues in select target proteins, which thus far remains the only known function of PRMTs (11, 19) . In this study,
we could show that all PRMT isoforms are expressed in the mouse lung by RT-PCR, Western blot, and immunohistochemical analysis. We were able to detect full-length mRNAs corresponding to the entire open reading frames of PRMT1-7 by RT-PCR, with corresponding protein expression patterns for PRMT1-6. Although three splice variants have been described for PRMT1 (20) and four splice-variants have been described for PRMT4 (21) , no evidence of alternative splicing was observed in the mouse lung (Figure 1 ). We were unable to detect PRMT7
protein expression, as we were lacking suitable antibodies for detection by Western Blot or immunohistochemistry, respectively. However, our report constitutes the first report of PRMT7 15 in the mouse. Much to our interest, PRMT isoforms were expressed in the bronchial and alveolar epithelium, suggesting an important role for PRMT function in this pulmonary compartment.
We detected a significant increase in PRMT2 mRNA and protein expression in animals subjected to 3 weeks of chronic hypoxia, which coincided with increased protein methylation in lung homogenates. Assuming constant protein turnover, this would be expected to lead to increased ADMA concentrations under hypoxia, which has indeed been demonstrated previously in hypoxic lungs (22) . In a recent study, Millatt et al. demonstrated increased lung ADMA levels in hypoxic rat lungs, which coincided with decreased dimethylarginine dimethylaminohydrolase (DDAH) I expression and activity (22) . DDAH I and II are the enzymes responsible for ADMA degradation. In addition, chronic hypoxia also leads to decreased expression of the second known ADMA metabolizing enzyme DDAH II in pig lungs (23), thus confirming the observation that hypoxia affects lung ADMA levels via dual regulation of the PRMT-ADMA-DDAH axis: it increases PRMT expression and concomitantly decreases DDAH expression, thus leading to a synergistic overall accumulation of ADMA concentrations.
Interestingly, PRMT and DDAH isoforms both localize to bronchial epithelial cells, suggesting a physiological role for these enzymes in lung epithelial homeostasis. While PRMTs in vascular smooth muscle have been suggested to be part of the systemic arginine-ADMA metabolism (10), the role of PRMT expression in bronchial and alveolar epithelial cells is intriguing and remains to be elucidated. Since ADMA can act as an endogenous inhibitor of NOS enzymes, a system of crucial importance for the alveolar-endothelial crosstalk, PRMT in bronchial and alveolar epithelial cells may represent an important local regulatory system for NO release and activity in the lung.
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A synergistic effect of hypoxia on PRMT, DDAH, and NOS activity in the lung is suggested to lead to increased vasoconstriction and vascular remodeling (22) (23) (24) (25) . PRMT activity may thus be directly linked to the NO system by ADMA generation. Pathophysiological roles for ADMA as an endogenous NOS inhibitor have indeed been suggested in several cardiovascular diseases, including atherosclerosis, hypertension, or diabetes (26) (27) (28) (29) (30) (31) (32) . It is highly unlikely,
however, that such a complex system (i.e. the evolvement of seven divergent PRMT isoforms) merely serves to generate a chemically rather simple byproduct (i.e. ADMA or SDMA). In this respect, the PRMT system probably serves additional roles that remain elusive. Several investigators have suggested that the post-translational modification of target proteins by PRMT arginine methylation modulates protein function (19, (33) (34) (35) (36) . Among the proteins identified thus far are RNA binding proteins, such as Sam68 (37) and proteins involved in signal transduction, such as STAT-1 (38), STAT-6 (39), or the EWS protein (40) . The time course and target arginine residues in these examples have been well described, but relatively little is known about the effects of methylation on protein function. Furthermore, no substrate of PRMT2 has been described to date, although several molecules with proposed roles in tissue remodelling and respiratory physiology are known to form a complexes with PRMT2, including estrogen receptor α, retinoic acid receptor α and peroxisome proliferator activated receptor γ, which have proposed roles in tissue remodelling and respiratory physiology (41) . In this respect, the high expression levels of PRMT isoforms in the lung observed in our studies may indicate an as yet uncharacterized function in pulmonary physiology and pathophysiology. Selective manipulation of PRMT expression or activity in the lung may therefore serve as a valuable tool to uncover novel physiological and pathophysiological roles of PRMT biology. 
